399 related articles for article (PubMed ID: 23803592)
1. Hypertension and kidneys: unraveling complex molecular mechanisms underlying hypertensive renal damage.
Mennuni S; Rubattu S; Pierelli G; Tocci G; Fofi C; Volpe M
J Hum Hypertens; 2014 Feb; 28(2):74-9. PubMed ID: 23803592
[TBL] [Abstract][Full Text] [Related]
2. [Slowing the progression of chronic renal insufficiency with captopril in rats with spontaneous arterial hypertension and adriamycin nephropathy].
Jovanović DB; Jovović Dj; Varagić J; Dimitrijević J; Dragojlović Z; Djukanović L
Srp Arh Celok Lek; 2002; 130(3-4):73-80. PubMed ID: 12154518
[TBL] [Abstract][Full Text] [Related]
3. Conflicting roles of 20-HETE in hypertension and renal end organ damage.
Zhang C; Booz GW; Yu Q; He X; Wang S; Fan F
Eur J Pharmacol; 2018 Aug; 833():190-200. PubMed ID: 29886242
[TBL] [Abstract][Full Text] [Related]
4. N-Palmitoylethanolamide protects the kidney from hypertensive injury in spontaneously hypertensive rats via inhibition of oxidative stress.
Mattace Raso G; Simeoli R; Russo R; Santoro A; Pirozzi C; d'Emmanuele di Villa Bianca R; Mitidieri E; Paciello O; Pagano TB; Orefice NS; Meli R; Calignano A
Pharmacol Res; 2013 Oct; 76():67-76. PubMed ID: 23917217
[TBL] [Abstract][Full Text] [Related]
5. Evidence for renoprotection by blockade of the renin-angiotensin-aldosterone system in hypertension and diabetes.
Karalliedde J; Viberti G
J Hum Hypertens; 2006 Apr; 20(4):239-53. PubMed ID: 16452996
[TBL] [Abstract][Full Text] [Related]
6. Progression of hypertension and kidney disease in aging fawn-hooded rats is mediated by enhanced influence of renin-angiotensin system and suppression of nitric oxide system and epoxyeicosanoids.
Doleželová Š; Jíchová Š; Husková Z; Vojtíšková A; Kujal P; Hošková L; Kautzner J; Sadowski J; Červenka L; Kopkan L
Clin Exp Hypertens; 2016; 38(7):644-651. PubMed ID: 27669111
[TBL] [Abstract][Full Text] [Related]
7. A model-based approach to investigating the pathophysiological mechanisms of hypertension and response to antihypertensive therapies: extending the Guyton model.
Hallow KM; Lo A; Beh J; Rodrigo M; Ermakov S; Friedman S; de Leon H; Sarkar A; Xiong Y; Sarangapani R; Schmidt H; Webb R; Kondic AG
Am J Physiol Regul Integr Comp Physiol; 2014 May; 306(9):R647-62. PubMed ID: 24500431
[TBL] [Abstract][Full Text] [Related]
8. [Are all antihypertensive drugs renoprotective?].
Wolf S; Risler T
Herz; 2004 May; 29(3):248-54. PubMed ID: 15167950
[TBL] [Abstract][Full Text] [Related]
9. Benazepril, an angiotensin-converting enzyme inhibitor, alleviates renal injury in spontaneously hypertensive rats by inhibiting advanced glycation end-product-mediated pathways.
Liu XP; Pang YJ; Zhu WW; Zhao TT; Zheng M; Wang YB; Sun ZJ; Sun SJ
Clin Exp Pharmacol Physiol; 2009 Mar; 36(3):287-96. PubMed ID: 19018797
[TBL] [Abstract][Full Text] [Related]
10. Antihypertensive treatment and renal protection: the role of drugs inhibiting the renin-angiotensin-aldosterone system.
Viazzi F; Leoncini G; Pontremoli R
High Blood Press Cardiovasc Prev; 2013 Dec; 20(4):273-82. PubMed ID: 24092648
[TBL] [Abstract][Full Text] [Related]
11. Tempol or candesartan prevents high-fat diet-induced hypertension and renal damage in spontaneously hypertensive rats.
Chung S; Park CW; Shin SJ; Lim JH; Chung HW; Youn DY; Kim HW; Kim BS; Lee JH; Kim GH; Chang YS
Nephrol Dial Transplant; 2010 Feb; 25(2):389-99. PubMed ID: 19749146
[TBL] [Abstract][Full Text] [Related]
12. Cellular mediators of renal vascular dysfunction in hypertension.
Ponnuchamy B; Khalil RA
Am J Physiol Regul Integr Comp Physiol; 2009 Apr; 296(4):R1001-18. PubMed ID: 19225145
[TBL] [Abstract][Full Text] [Related]
13. Renal and cardio-protective effects of direct renin inhibition: a systematic literature review.
Lambers Heerspink HJ; Perkovic V; de Zeeuw D
J Hypertens; 2009 Dec; 27(12):2321-31. PubMed ID: 19727007
[TBL] [Abstract][Full Text] [Related]
14. Role of the renin-angiotensin system in kidney development and programming of adult blood pressure.
Almeida LF; Tofteng SS; Madsen K; Jensen BL
Clin Sci (Lond); 2020 Mar; 134(6):641-656. PubMed ID: 32219345
[TBL] [Abstract][Full Text] [Related]
15. Renal protection with angiotensin receptor blockers: where do we stand.
Schmieder RE; Ruilope LM; Barnett AH
J Nephrol; 2011; 24(5):569-80. PubMed ID: 21404225
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the cardioprotective and renoprotective effects of the L/N-type calcium channel blocker, cilnidipine, in adriamycin-treated spontaneously-hypertensive rats.
Aritomi S; Harada E; Sugino K; Nishimura M; Nakamura T; Takahara A
Clin Exp Pharmacol Physiol; 2015 Apr; 42(4):344-52. PubMed ID: 25582553
[TBL] [Abstract][Full Text] [Related]
17. Blockade of the renin-angiotensin-aldosterone system: effects on hypertensive target organ damage.
Grandi AM; Maresca AM
Cardiovasc Hematol Agents Med Chem; 2006 Jul; 4(3):219-28. PubMed ID: 16842207
[TBL] [Abstract][Full Text] [Related]
18. Renal oxidative stress, oxygenation, and hypertension.
Palm F; Nordquist L
Am J Physiol Regul Integr Comp Physiol; 2011 Nov; 301(5):R1229-41. PubMed ID: 21832206
[TBL] [Abstract][Full Text] [Related]
19. The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.
Heerspink HJ; Gao P; de Zeeuw D; Clase C; Dagenais GR; Sleight P; Lonn E; Teo KT; Yusuf S; Mann JF
Eur J Prev Cardiol; 2014 Mar; 21(3):299-309. PubMed ID: 24191305
[TBL] [Abstract][Full Text] [Related]
20. Renal protection and antihypertensive drugs: current status.
Salvetti A; Mattei P; Sudano I
Drugs; 1999 May; 57(5):665-93. PubMed ID: 10353294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
